Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Disentangling verbal learning performance in multiple sclerosis: Dissociating strategy initiation and maintenance.

The Clinical neuropsychologist·2026
Same author

Sustained Effects of Physiotherapy Interventions on Balance, Gait, and General Motor Function in Patients with Parkinson's Disease: A Systematic Review and Meta-Analysis.

NeuroSci·2026
Same author

Verbal fluency in multiple sclerosis and neuromyelitis optica spectrum disorders: a systematic review and meta-analysis.

Journal of clinical and experimental neuropsychology·2026
Same author

Effects of cognitive and language decline on communication in mild cognitive impairment: An integrative systematic review.

Applied neuropsychology. Adult·2026
Same author

Neuropsychological Sequelae and Neuroradiological Correlates of Arachnoid Cysts in Adults: A Systematic Review.

Brain sciences·2026
Same author

An Investigation of the Effect of Exercise on Sleep Disturbances and Fatigue Symptoms in Patients Diagnosed with Primary Brain Tumors: A Systematic Review.

NeuroSci·2026
Same journal

The Neuropsychiatric Phenotype of Klüver-Bucy Syndrome: A Systematic Review of Reported Cases.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Diffusion Tensor Imaging Correlates of Financial Capacity Instrument-Short Form Completion Time in Mild Cognitive Impairment.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

A 3-Week Intensive Outpatient Program for Patients With Persistent Neuropsychiatric Symptoms After Remote TBI.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Outcomes of Integrated Practice Unit Treatment for Mild Traumatic Brain Injury and Co-occurring Conditions Among Veterans.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Case Study 12: A 57-Year-Old Man With Seizures, Paranoid Psychosis, and Catatonia.

The Journal of neuropsychiatry and clinical neurosciences·2026
Same journal

Rates of Comorbid Psychiatric Conditions Among Adults With Hydrocephalus at a Hydrocephalus Specialty Center.

The Journal of neuropsychiatry and clinical neurosciences·2026
See all related articles

Related Experiment Video

Updated: Jul 7, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Multiple sclerosis, cannabinoids, and cognition.

Panagiotis Papathanasopoulos1, Lambros Messinis, Epameinondas Lyros

  • 1Department of Neurology, Neuropsychology Section, University of Patras Medical School, Rion, Patras, Greece.

The Journal of Neuropsychiatry and Clinical Neurosciences
|February 29, 2008
PubMed
Summary
This summary is machine-generated.

Cannabis-based medicines show therapeutic potential for multiple sclerosis, with short-term use not causing cognitive decline. Long-term effects on cognition require further research in large clinical trials.

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Related Experiment Videos

Last Updated: Jul 7, 2026

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is a chronic neurological disease affecting cognition.
  • Cannabis-based medicinal extracts (CBMEs) are being explored for MS symptom management.
  • Concerns exist regarding potential cognitive side effects of CBMEs.

Purpose of the Study:

  • To critically review the existing literature on the cognitive effects of CBMEs in multiple sclerosis.
  • To assess the potential for adverse cognitive effects from long-term cannabinoid use in MS therapeutics.

Main Methods:

  • Literature review of current research on CBMEs and cognition in MS.
  • Analysis of data regarding short-term vs. long-term cannabis use and cognitive function.
  • Evaluation of the need for large-scale clinical trials.

Main Results:

  • Short-term administration of CBMEs in MS does not appear to cause significant cognitive decline.
  • Cognitive deficits linked to recreational cannabis use may not apply to pharmaceutical use.
  • Limited data exists on long-term cognitive effects due to a lack of extensive clinical trials.

Conclusions:

  • CBMEs may offer therapeutic benefits for multiple sclerosis.
  • Further large-scale, long-term clinical trials are essential to fully understand the cognitive safety profile of CBMEs in MS.
  • Unresolved questions remain regarding the long-term impact of cannabinoids on MS cognition.